Perspective Therapeutics Reports Sustained Tumor Response with Lead-212 Radiopharmaceutical in Neuroendocrine Tumors
Key Insights
Perspective Therapeutics presented updated interim data showing [212Pb]VMT-α-NET achieved a 39% objective response rate in patients with SSTR2-expressing neuroendocrine tumors at the 5.0 mCi dose level.
The radiopharmaceutical demonstrated sustained anti-tumor activity with 76% of patients remaining progression-free and alive after additional 13 weeks of follow-up, including evidence of deepening tumor responses.
Safety analysis of 56 patients showed no dose-limiting toxicities or treatment-related discontinuations, with the company cleared to advance to higher dose testing at 6.0 mCi.
Perspective Therapeutics presented updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET at the 2026 ASCO Gastrointestinal Cancers Symposium, demonstrating sustained anti-tumor activity and favorable tolerability in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors.
The updated analysis, with a data cut-off date of December 10, 2025, included safety data from 56 patients across three dose cohorts and efficacy analysis from 25 patients in the first two cohorts. Results showed an additional ~13 weeks of follow-up since the previous presentation at the European Society for Medical Oncology Congress in October 2025.
Efficacy Demonstrates Durable Disease Control
Among the 25 patients evaluated for efficacy, 19 patients (76%) remained without progression and alive, including both patients in Cohort 1 (2.5 mCi dose). In Cohort 2 (5.0 mCi dose), nine patients (39%) achieved objective response according to investigator-assessed RECIST v1.1, with eight confirmed responses previously reported and one additional patient experiencing an initial response since the prior update.
The analysis revealed evidence of deepening tumor responses, with seven patients observed to have deepening of best response, including one patient with stable disease. All 23 patients in Cohort 2 had at least one tumor expressing SSTR2, and among the 16 patients with SSTR2 expression in all tumors, seven (44%) achieved confirmed responses and 14 (87.5%) remained progression-free with a median follow-up of 41 weeks.
Safety Profile Supports Dose Escalation
The safety analysis encompassed 56 patients who received at least one treatment: two patients in Cohort 1 (2.5 mCi), 46 patients in Cohort 2 (5.0 mCi), and eight patients in Cohort 3 (6.0 mCi). No dose limiting toxicities, treatment-related discontinuations, serious renal complications, dysphagia, or clinically significant treatment-related myelosuppression were reported.
Grade 3 or higher treatment-emergent adverse events occurred in 21 patients (37.5%). One patient in Cohort 3 experienced a transient Grade 4 lymphocyte count decrease that resolved without medical intervention, with the patient continuing treatment. No Grade 5 events were reported, and serious adverse events in five patients were deemed unrelated to the study medication.
The dose limiting toxicity assessment for Cohort 3 (6.0 mCi) was completed as planned, clearing the path to treat additional patients at this dose level, with one additional patient already treated.
Clinical Development Strategy
"With longer follow-up and a growing body of clinical experience, we continue to see evidence of sustained and deepening anti-tumor activity for VMT-α-NET at the dose level evaluated in Cohort 2, while the favorable tolerability profile is maintained, possibly even at a higher dose," said Vikas Prasad, MD, Professor of Radiology at Washington University School of Medicine's Siteman Cancer Center.
Markus Puhlmann, Chief Medical Officer of Perspective, noted that the updated results support VMT-α-NET's clinical profile at the 5 mCi dose and expressed confidence in meaningful regulatory engagement during 2026 for proceeding to registrational trials.
About the Treatment Approach
[212Pb]VMT-α-NET is designed to target and deliver lead-212 to tumor sites expressing SSTR2. The multi-center, open-label, dose-escalation study (NCT05636618) enrolls patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received prior radiopharmaceutical therapy and whose tumors showed radiological progression within 12 months prior to enrollment.
Initial efficacy data for the remaining patients in Cohort 2 and eight patients in Cohort 3 are pending, with submissions to additional medical conferences planned for 2026. The company's radiopharmaceutical platform utilizes the alpha-emitting isotope 212Pb to deliver targeted radiation specifically to cancer cells, part of a "theranostic" approach that enables both imaging and treatment capabilities.